RON and cisplatin resistance in ovarian cancer cell lines

Oncology Research

Volumn 19, Issue 1, 2010, Pages 13-22

  Prislei, Silvia ^a   Mariani, Marisa ^a   Raspaglio, Giuseppina ^a   Mozzetti, Simona ^a   Filippetti, Flavia ^a   Ferrandina, Gabriella ^b   Scambia, Giovanni ^a   Ferlini, Cristiano ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemoresistance; Ovarian cancer; RON; Tyrosine kinase receptor

Indexed keywords

CISPLATIN; DOXORUBICIN; MESSENGER RNA; PACLITAXEL; RECEPTOR ANTIBODY; TYROSINE KINASE RECEPTOR; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL LINE; CELL STRUCTURE; CHEMOSENSITIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; STABLE EXPRESSION;

EID: 79951486305     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12828372551713     Document Type: Article

References (38)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin. 57:43-66; 2007.
2. Benvenuti, S.; Comoglio, P. M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell Physiol. 213:316-325; 2007.
3. Leonis, M. A.; Thobe, M. N.; Waltz, S. E. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol. 3:441-448; 2007.
4. Wagh, P. K.; Peace, B. E.; Waltz, S. E. Met-related receptor tyrosine kinase RON in tumor growth and metastasis. Adv. Cancer Res. 100:1-33; 2008.
5. Chen, Y. Q.; Zhou, Y. Q.; Fisher, J. H.; Wang, M. H. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: Oncogenic potential of RON in vivo. Oncogene 21:6382-6386; 2002.
6. Peace, B. E.; Toney-Earley, K.; Collins, M. H.; Waltz, S. E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res. 65:1285-1293; 2005.
7. Chan, E. L.; Peace, B. E.; Collins, M. H.; Toney-Earley, K.; Waltz, S. E. Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 24:479-488; 2005.
8. Zinser, G. M.; Leonis, M. A.; Toney, K.; Pathrose, P.; Thobe, M.; Kader, S. A.; Peace, B. E.; Beauman, S. R.; Collins, M. H.; Waltz, S. E. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 66:11967-11974; 2006.
9. Maggiora, P.; Lorenzato, A.; Fracchioli, S.; Costa, B.; Castagnaro, M.; Arisio, R.; Katsaros, D.; Massobrio, M.; Comoglio, P. M.; Di Renzo, M. F. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell. Res. 288:382-389; 2003.
10. Brahimi-Horn, M. C.; Chiche, J.; Pouysségur, J. Hypoxia and cancer. J. Mol. Med. 85:1301-1307; 2007.
11. Chan, D. A.; Giaccia, A. J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 26:333-339; 2007.
12. Ruan, K.; Song, G.; Ouyang, G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 107:1053-1062; 2009.
13. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361; 2003.
14. Ferlini, C.; Raspaglio, G.; Mozzetti, S.; Cicchillitti, L.; Filippetti, F.; Gallo, D.; Fattorusso, C.; Campiani, G.; Scambia, G. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 65:2397-2405; 2005.
15. Steffensen, K. D.; Waldstrom, M.; Jakobsen, A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19:820-825; 2009
16. Selvakumaran, M.; Pisarcik, D. A.; Bao, R.; Yeung, A. T.; Hamilton, T. C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63:1311-1316; 2003
17. Shahzad, M. M. K.; Lopez-Berestein, G.; Sood, A. K. Novel strategies for reversing platinum resistance. Drug Resistance Updates 12:148-152; 2009
18. Montero-Julian, F. A.; Dauny, I.; Flavetta, S.; Ronsin, C.; André, F.; Xerri, L.; Wang, M. H.; Marvaldi, J.; Breath nach, R.; Brailly, H. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor. Hybridoma 17:541-551; 1998.
19. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22:27-55; 1984.
20. Feres, K. J.; Ischenko, I.; Hayman, M. J. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 28:279-288; 2009.
21. Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M. C.; Longati, P.; Comoglio, P. M. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19:3041-3049; 2000.
22. Peace, B. E.; Hill, K. J.; Degen, S. J.; Waltz, S. E. Crosstalk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp. Cell. Res. 289:317-325; 2003.
23. Ferrandina, G.; Martinelli, E.; Petrillo, M.; Prisco, M. G.; Zucconi, A.; Santaguida, S.; Zannoni, G.; Scambia, G.; Ferlini, C. Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. Gynecol. Oncol. 111:237-243; 2008.
24. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Jänne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043; 2007.
25. Engelman, J. A.; Jänne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14:2895-2899; 2008
26. Shattuck, D. L.; Miller, J. K.; Carraway, 3rd, K. L.; Sweeney, C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68:1471-1477; 2008.
27. Mueller, K. L.; Hunter, L. A.; Ethier, S. P.; Boerner, J. L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 68:3314-3322; 2008.
28. Agarwal, S.; Zerillo, C.; Kolmakova, J.; Christensen, J. G.; Harris, L. N.; Rimm, D. L.; Digiovanna, M. P.; Stern, D. F. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer 100:941-949; 2009.
29. Pillay, V.; Allaf, L.; Wilding, A. L.; Donoghue, J. F.; Court, N. W.; Greenall, S. A.; Scott, A. M.; Johns, T. G. The plasticity of oncogene addiction: Implication for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11:448-458; 2009.gete
30. Kitajima, Y.; Ide, T.; Ohtsuka, T.; Miyazaki, K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 9:1341-1347; 2008.
31. Thangasamy, A.; Rogge, J.; Ammanamanchi, S. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells. J. Biol. Chem. 284:14001-14010; 2009.
32. Imai, T.; Horiuchi, A.; Wang, C.; Oka, K.; Ohira, S.; Nikaido, T.; Konishi, I. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163:1437-1447; 2003.
33. Bardella, C.; Costa, B.; Maggiora, P.; Patané, S.; Olivero, M.; Ranzani, G. N.; De Bortoli, M.; Comoglio, P. M.; Di Renzo, M. F. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 64: 5154-5161; 2004.
34. Wang, D.; Shen, Q.; Xu, X. M.; Chen, Y. Q.; Wang, M. H. Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells. Carcinogenesis 6:27-36; 2005.
35. Camp, E. R.; Liu, W.; Fan, F.; Yang, A.; Somcio, R.; Ellis, L. M. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann. Surg. Oncol. 12: 273-281; 2005.
36. O'Toole, J. M.; Rabenau, K. E.; Burns, K.; Lu, D.; Mangalampalli, V.; Balderes, P.; Covino, N.; Bassi, R.; Prewett, M.; Gottfredsen, K. J.; Thobe, M. N.; Cheng, Y.; Li, Y.; Hicklin, D. J.; Zhu, Z.; Waltz, S. E.; Hayman, M. J.; Ludwig, D. L.; Pereira, D. S. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 66:9162-9170; 2006.
37. Zhang, Y.; Kaplan-Lefko, P. J.; Rex, K.; Yang, Y.; Moriguchi, J.; Osgood, T.; Mattson, B.; Coxon, A.; Reese, M.; Kim, T. S.; Lin, J.; Chen, A.; Burgess, T. L.; Dussault, I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 68:6680-6687; 2008.
38. Dussault, I.; Bellon, S. F. From concept to reality: The long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med. Chem. 9:221-229; 2009.